Company
Headquarters: Taipei, Taiwan
Employees: 89
TW$4.14 Billion
TWD as of Jan. 1, 2024
US$134.8 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Intech Biopharm Corporation focuses on developing and manufacturing generic drugs to treat respiratory diseases. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform to treat asthma and chronic pulmonary obstructive disease; and dry powder inhaler. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Intech Biopharm Corp has the following listings and related stock indices.
Stock: TWSE: 6461 wb_incandescent